Display options
Cite
Broséus J, Mourah S, Ramstein G, et al. VEGF. Oncotarget. 2017;8(53):90808-90824doi: 10.18632/oncotarget.19385.
Broséus, J., Mourah, S., Ramstein, G., Bernard, S., Mounier, N., Cuccuini, W., Gaulard, P., Gisselbrecht, C., Brière, J., Houlgatte, R., & Thieblemont, C. (2017). VEGF. Oncotarget, 8(53), 90808-90824. https://doi.org/10.18632/oncotarget.19385
Broséus, Julien, et al. "VEGF." Oncotarget vol. 8,53 (2017): 90808-90824. doi: https://doi.org/10.18632/oncotarget.19385
Broséus J, Mourah S, Ramstein G, Bernard S, Mounier N, Cuccuini W, Gaulard P, Gisselbrecht C, Brière J, Houlgatte R, Thieblemont C. VEGF. Oncotarget. 2017 Jul 19;8(53):90808-90824. doi: 10.18632/oncotarget.19385. eCollection 2017 Oct 31. PMID: 29207605; PMCID: PMC5710886.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 19;8(53):90808-90824. doi: 10.18632/oncotarget.19385. eCollection 2017 Oct 31.

VEGF.

Oncotarget

Julien Broséus, Samia Mourah, Gérard Ramstein, Sophie Bernard, Nicolas Mounier, Wendy Cuccuini, Philippe Gaulard, Christian Gisselbrecht, Josette Brière, Rémi Houlgatte, Catherine Thieblemont

Affiliations

  1. Inserm U954, Faculty of Medicine, University of Lorraine, Nancy, France.
  2. University Hospital of Nancy, Hematology Laboratory, Nancy, France.
  3. Paris Diderot University, Sorbonne Paris Cité, Paris, France.
  4. APHP, Saint Louis University Hospital, Pharmacology-Biologic Laboratory, Paris, France.
  5. Inserm UMRS 976, France.
  6. LS2N - DUKe, University of Nantes, Nantes, France.
  7. APHP, Saint-Louis University Hospital, Hemato-Oncology, Paris, France.
  8. University Hospital of L'archet, Nice, France.
  9. APHP, Saint-Louis University Hospital, Hematology Laboratory, Paris, France.
  10. Department of Pathology, APHP, Henri Mondor University Hospital, Creteil, France.
  11. Inserm U955, University Paris-Est, Créteil, France.
  12. Lymphoma Study Association, Pierre-Bénite, France.
  13. Department of Pathology, APHP, Saint-Louis University Hospital, Paris, France.
  14. University Hospital of Nancy, DRCI, Nancy, France.

PMID: 29207605 PMCID: PMC5710886 DOI: 10.18632/oncotarget.19385

Abstract

Tumor microenvironment including endothelial and immune cells plays a crucial role in tumor progression and has been shown to dramatically influence cancer survival. In this study, we investigated the clinical relevance of the gene expression of key mediators of angiogenesis, VEGF isoforms 121, 165, and 189, and their receptors (VEGFR-1 and R-2) in a cohort of patients (

Keywords: ABC; angiogenesis; cancer; immune response; like DLBCL

Conflict of interest statement

CONFLICTS OF INTEREST Professor C. Gisselbrecht: Research funding by Roche. The other authors declare no competing financial interests.

References

  1. Bioinformatics. 2002 Feb;18(2):251-60 - PubMed
  2. J Clin Oncol. 2010 Sep 20;28(27):4184-90 - PubMed
  3. Eur J Haematol. 2002 Feb;68(2):91-100 - PubMed
  4. Cytokine Growth Factor Rev. 2014 Feb;25(1):1-19 - PubMed
  5. Leuk Lymphoma. 2017 Nov;58(11):2677-2682 - PubMed
  6. Science. 2008 Mar 21;319(5870):1676-9 - PubMed
  7. Genes Dev. 2008 Mar 1;22(5):559-74 - PubMed
  8. Nat Med. 2002 Jan;8(1):68-74 - PubMed
  9. Oncotarget. 2016 Dec 20;7(51):83987-84002 - PubMed
  10. N Engl J Med. 2004 Jun 3;350(23 ):2335-42 - PubMed
  11. J Cell Biol. 2010 Feb 22;188(4):595-609 - PubMed
  12. Genome Biol. 2014 Aug 15;15(8):432 - PubMed
  13. Endocr Rev. 2004 Aug;25(4):581-611 - PubMed
  14. J Cancer Res Ther. 2016 Apr-Jun;12 (2):605-11 - PubMed
  15. Oncologist. 2007 Jun;12(6):713-8 - PubMed
  16. J Clin Oncol. 2011 May 10;29(14):1864-75 - PubMed
  17. Int J Cancer. 2013 Dec 1;133(11):2563-76 - PubMed
  18. J Clin Oncol. 2012 Dec 20;30(36):4462-9 - PubMed
  19. Nat Rev Cancer. 2010 Feb;10 (2):138-46 - PubMed
  20. FEBS Lett. 2002 Mar 13;514(2-3):115-21 - PubMed
  21. Kidney Int. 2015 May;87(5):984-95 - PubMed
  22. Blood. 2011 Aug 4;118(5):1350-8 - PubMed
  23. N Engl J Med. 2008 Nov 27;359(22):2313-23 - PubMed
  24. J Clin Oncol. 2011 Nov 1;29(31):4079-87 - PubMed
  25. Cancer Res. 2006 Jan 15;66(2):820-7 - PubMed
  26. Blood. 2004 Nov 1;104(9):2893-902 - PubMed
  27. Oncogene. 2005 Jul 7;24(29):4660-71 - PubMed
  28. Nat Med. 2003 Jun;9(6):669-76 - PubMed
  29. Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):277-83 - PubMed
  30. Blood Cancer J. 2015 Aug 28;5:e346 - PubMed
  31. Nucleic Acids Res. 2002 Feb 15;30(4):e15 - PubMed
  32. N Engl J Med. 2010 Apr 15;362(15):1417-29 - PubMed
  33. Genes Chromosomes Cancer. 2016 Mar;55(3):251-67 - PubMed
  34. Blood. 2011 Feb 24;117(8):2423-32 - PubMed
  35. Oncotarget. 2016 Aug 9;7(32):51494-51502 - PubMed
  36. Nature. 2000 Feb 3;403(6769):503-11 - PubMed
  37. Nature. 1993 Apr 29;362(6423):841-4 - PubMed
  38. Blood. 2013 Feb 21;121(8):1367-76 - PubMed
  39. Blood. 2012 May 17;119(20):4619-24 - PubMed
  40. Blood. 2000 Dec 1;96(12):3712-8 - PubMed
  41. Nature. 2011 May 19;473(7347):298-307 - PubMed
  42. Blood. 2009 Jun 11;113(24):6069-76 - PubMed
  43. Genome Biol. 2003;4(4):R28 - PubMed
  44. PLoS One. 2010 May 19;5(5):e10715 - PubMed
  45. Exp Hematol Oncol. 2012 Aug 22;1(1):22 - PubMed
  46. Blood. 2014 Jan 30;123(5):678-86 - PubMed
  47. Oncotarget. 2016 Dec 27;7(52):86433-86445 - PubMed
  48. Clin Cancer Res. 2016 May 1;22(9):2290-300 - PubMed
  49. Gene. 2004 Oct 27;341:291-304 - PubMed
  50. N Engl J Med. 2002 Jun 20;346(25):1937-47 - PubMed
  51. Nat Genet. 2000 May;25(1):25-9 - PubMed
  52. Br J Haematol. 1999 Aug;106(2):504-9 - PubMed
  53. Cancer Res. 2009 Aug 15;69(16):6387-95 - PubMed
  54. Leukemia. 2008 Oct;22(10 ):1917-24 - PubMed
  55. Curr Oncol Rep. 2009 Sep;11(5):386-93 - PubMed
  56. Nature. 2006 May 4;441(7089):106-10 - PubMed

Publication Types